Diagnostic

Parasight System Inc. aims to address the inefficiencies and inaccuracies in traditional veterinary diagnostic methods. Current approaches to fecal exams, heartworm detection, and Lyme disease testing often rely on manual processes that are time-consuming, prone to error, and dependent on subjective interpretation. This can lead to missed diagnoses or delayed treatments, ultimately affecting the health and well-being of animals. Parasight System's solution leverages advanced AI technology and antigen-based fluorescence detection to automate and enhance diagnostic accuracy.

Atlas Endoscopy is addressing critical inefficiencies in colorectal cancer screening and diagnosis, where traditional colonoscopy faces significant limitations. Over 80 million colonoscopies are performed annually worldwide, yet accessibility remains a challenge due to the need for sedation, risk of cross contamination due to the reusable colonoscope, and specialized facilities.

Imagine Devices Inc. specializes in minimally invasive solutions for vital sign monitoring in clinical care. Our flagship product, the Trinity Tube, is a sterile, multifunctional feeding catheter designed to address critical unmet needs in neonatal intensive care units (NICUs). It enhances safety, accuracy, and efficiency in the care of premature infants by integrating feeding, abdominal gas venting, and vital sign monitoring into a single device.

Augment Health is addressing chronic bladder dysfunction facing 7M US patients following neurologic injury or disease — a $12.3B annual market opportunity. Urodynamic studies are the primary diagnostic for this patient population, but major barriers exist: 60% of US counties lack a urologist, scheduling can be delayed up to 5 months, and 44% of tests are non-diagnostic. Nearly 200K patients are actively seeking urodynamics but unable to access it, representing a $114M initially obtainable market.

Globally, more than one billion individuals suffer from neuropsychiatric and mental health disorders, which has led to an increased demand for medical help.  Approximately 77 million individuals in the U.S. are on antidepressants, anti-anxiety, antipsychotics, and mood stabilizers, and 30% to 60% are treatment-resistant to these drugs.